During the press conference, MOH’s director of medical services Kenneth Mak said the Health Sciences Authority is completing the process of evaluating the Novavax vaccine and is expected to release a statement soon.
“We are very optimistic that we will be able to get authorisation to use the Novavax vaccine as part of our national vaccination programme and the (expert committee is) working through what the recommendations will be,” Assoc Prof Mak said.
If the vaccine is used, authorities expect it to have an “important role” as a non-mRNA vaccine alternative for the purposes of boosting the population, he added.
“(The) evidence today shows a better vaccine effectiveness against the Delta and Omicron compared to some other non-mRNA vaccines that we have available in Singapore. So, it is a very high likelihood that we will make further recommendations concerning the use of Novavax as a booster vaccine as part of the national vaccination programme.”